Recurrent Head and Neck Squamous Cell Carcinoma Clinical Trials

52 clinical trials for Recurrent Head and Neck Squamous Cell Carcinoma across international registries, including 21 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma — RECRUITING · PHASE1
• Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment — RECRUITING · PHASE3
• Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer — RECRUITING · PHASE2
• Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma — RECRUITING · PHASE2
• PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC — RECRUITING · PHASE2
• Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS≥1) HNSCC — RECRUITING · PHASE3
• FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC — RECRUITING · PHASE2
• Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer — RECRUITING · PHASE2
• Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation — RECRUITING · NA
• Phase I/ II Trial Combining PD-1 Inhibition and Neoadjuvant Proton or Photon Radiation Therapy in Recurrent Head and Neck Squamous Cell Carcinoma — RECRUITING · PHASE1
• Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC — RECRUITING · PHASE2
• Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study — RECRUITING · PHASE4
• Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program — RECRUITING · PHASE2
• BRIDGE Study: Neoadjuvant Finotonlimab, Cetuximab, and Docetaxel in Resectable Recurrent HNSCC After Immunotherapy Progression — RECRUITING · PHASE2
• A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma — RECRUITING · PHASE3
• Evaluating 111In Panitumumab for Nodal Staging in Head and Neck Cancer — RECRUITING · PHASE1
• TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer — RECRUITING · PHASE1
• Establishment of a Microfluidic Based Liquid Biopsy Platform for Recurrent/Metastatic Head and Neck Cancers Prognostication Using NK Cell IFN-γ Expression and CTM Correlation With DS-SACA Chip — RECRUITING
• Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial — RECRUITING · PHASE2
• A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases — RECRUITING · PHASE3
• Evaluating the Use of Dual Imaging Techniques for Detection of Disease in Patients With Head and Neck Cancer — RECRUITING · PHASE1
• CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer — ACTIVE_NOT_RECRUITING · PHASE1
• Anti-PD-1 Therapy in Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma — NOT_YET_RECRUITING · PHASE2
• Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers — ACTIVE_NOT_RECRUITING · PHASE2
• CIML NK Cell in Head & Neck Cancer — COMPLETED · PHASE1
• Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer — ACTIVE_NOT_RECRUITING · PHASE1
• Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery — ACTIVE_NOT_RECRUITING · PHASE1
• Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck — ACTIVE_NOT_RECRUITING · PHASE2
• Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck — ACTIVE_NOT_RECRUITING · PHASE2
• Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma — ACTIVE_NOT_RECRUITING · PHASE2
• Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors — ACTIVE_NOT_RECRUITING · PHASE1
• Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• NBTXR3, Radiation Therapy, and Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Cancer — TERMINATED · PHASE2
• Quad Shot Radiotherapy in Combination With Immune Checkpoint Inhibition — COMPLETED · PHASE2
• Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma — ACTIVE_NOT_RECRUITING · PHASE2
• Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC — COMPLETED · PHASE2
• An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors — ACTIVE_NOT_RECRUITING · PHASE1
• Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN — WITHDRAWN · PHASE2
• NT-I7 for the Treatment of Recurrent Squamous Cell Carcinoma of Head and Neck Undergoing Surgery — TERMINATED · PHASE1
• Phase II Trial of Pembrolizumab in Recurrent or Metastatic HNSCC — ACTIVE_NOT_RECRUITING · PHASE2
• Bintrafusp Alfa and Stereotactic Body Radiation Therapy for the Treatment of Recurrent or Second Primary Head and Neck Squamous Cell Cancer — TERMINATED · PHASE1
• Intensity-Modulated Radiation Therapy & Nivolumab for Recurrent or Second Primary Head & Neck Squamous Cell Cancer — COMPLETED · PHASE2
• Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma — COMPLETED · PHASE2
• Identification of Pattern and Factors Affecting Recurrence in Head and Neck Carcinoma — OTHER
• Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma — COMPLETED · PHASE1
• INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma — WITHDRAWN · PHASE2
• Re-irradiation With NBTXR3 in Combination With Pembrolizumab for the Treatment of Inoperable Locoregional Recurrent Head and Neck Squamous Cell Cancer — WITHDRAWN · PHASE2
• Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma — TERMINATED · PHASE1
• Optimizing Antitumor Immunity Using Plasmid Electroporation, Pembrolizumab, and Epacadostat — TERMINATED · PHASE2

Refine this search